Page last updated: 2024-11-07

2-(4-(dimethylamino)benzylidene)malononitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(4-(dimethylamino)benzylidene)malononitrile: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID137736
CHEMBL ID1461512
SCHEMBL ID1227106
MeSH IDM0576479

Synonyms (44)

Synonym
AKOS000442790
nsc 52860
benzene, 1-dimethylamino-4-(2,2-dicyanoethenyl)-
UPCMLD0ENAT0500-7677:001
HMS2568N11
MS-7365
benzene, 1-dimethylamino-4-(2,2-dicyanoethenyl)
p-n,n-dimethylaminobenzal malononitrile
nsc52860
2826-28-0
nsc-52860
DIVK1C_001853
smr000185220
[4-(dimethylamino)benzylidene]malononitrile
MLS000576193
CDS1_000813
MAYBRIDGE1_005565
[4-(dimethylamino)benzylidene]propanedinitrile
STK326756
HMS557E21
FT-0690555
2-(4-(dimethylamino)benzylidene)malononitrile
NCGC00245590-01
CHEMBL1461512
2-{[4-(dimethylamino)phenyl]methylidene}propanedinitrile
SCHEMBL1227106
4-dimethylaminobenzylidenemalononitrile
(4-dimethylaminobenzylidene)malodinitrile
2-[4-(dimethylamino)benzylidene]malononitrile #
IYNONQVNLZATDK-UHFFFAOYSA-N
(4-dimethylaminobenzyliden)-malodinitril
4-dicyanovinyl-n,n-dimethylaniline
DTXSID70182509
mfcd00100708
((4-(dimethylamino)phenyl)methylene)methane-1,1-dicarbonitrile
2-[4-(dimethylamino)benzylidene]malononitrile
4-(n,n-dimethylamino)benzalmalononitrile
2-[[4-(dimethylamino)phenyl]methylidene]propanedinitrile
2-[4-(dimethylamino)phenyl]ethylene-1,1-dinitrile
F1638-0084
CAA82628
CS-0316268
1-cyano-2-[4-(dimethylamino)phenyl]vinyl cyanide
Z44300006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency7.07950.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency10.00000.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID634972Inhibition of West Nile virus NS2B-NS3 protease expressed in Escherichia coli BL21 lambda (DE3) using Abz-GLKRGG-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins before substrate addition measured up to 15 mins by spectrofluorimetry2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases.
AID634971Inhibition of Dengue virus NS2B-NS3 protease expressed in Escherichia coli BL21 lambda (DE3) using Abz-NleKRRS-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins before substrate addition measured up to 15 mins by spectrofluorimetry2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases.
AID634973Inhibition of human thrombin using Boc-VPR-AMC as substrate at 25 uM preincubated for 15 mins before substrate addition measured up to 10 mins by spectrofluorimetry2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.29 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]